RESUMO
OBJECTIVE: The objective of this study was to evaluate the minimum number of required cases for successful robotic retroperitoneal partial nephrectomy for an experienced surgeon in transperitoneal robotic surgery. METHODS: Our prospectively collected clinic database was evaluated retrospectively, and 50 patients who underwent robotic retroperitoneal partial nephrectomy by a single experienced surgeon from January 2019 to February 2023 were included in this study. Demographic and perioperative data and R.E.N.A.L. nephrometry scores were noted. margin, ischemia, and complication score was used to predict surgical success. Receiver operating characteristic curve analysis was used to determine how many cases were required to achieve margin, ischemia, and complication score positivity and to apply the off-clamp technique. Also, the first 25 patients were assigned to Group 1 and the second 25 patients to Group 2, and the data were compared between the groups. RESULTS: The patients' demographic data and tumor characteristics were similar in the groups. The off-clamp technique and sutureless technique rates in Group 2 were significantly higher than that in Group 1. Margin, ischemia, and complication score positivity was observed in 60% (n=15) of Group 1 and 96% (n=24) of Group 2. At receiver operating characteristic curve analysis, the 25th and later cases were statistically significant in terms of margin, ischemia, and complication score positivity. In terms of performing surgery with the off-clamp technique, the 28th and subsequent cases were statistically significant. CONCLUSION: A total of 25 or more cases appear to be sufficient to provide optimal surgical results in robotic retroperitoneal partial nephrectomy for an experienced surgeon.
Assuntos
Neoplasias Renais , Procedimentos Cirúrgicos Robóticos , Humanos , Procedimentos Cirúrgicos Robóticos/efeitos adversos , Procedimentos Cirúrgicos Robóticos/métodos , Neoplasias Renais/cirurgia , Neoplasias Renais/patologia , Estudos Retrospectivos , Resultado do Tratamento , Nefrectomia/efeitos adversos , Nefrectomia/métodos , Isquemia/cirurgiaRESUMO
SUMMARY OBJECTIVE: The objective of this study was to evaluate the minimum number of required cases for successful robotic retroperitoneal partial nephrectomy for an experienced surgeon in transperitoneal robotic surgery. METHODS: Our prospectively collected clinic database was evaluated retrospectively, and 50 patients who underwent robotic retroperitoneal partial nephrectomy by a single experienced surgeon from January 2019 to February 2023 were included in this study. Demographic and perioperative data and R.E.N.A.L. nephrometry scores were noted. margin, ischemia, and complication score was used to predict surgical success. Receiver operating characteristic curve analysis was used to determine how many cases were required to achieve margin, ischemia, and complication score positivity and to apply the off-clamp technique. Also, the first 25 patients were assigned to Group 1 and the second 25 patients to Group 2, and the data were compared between the groups. RESULTS: The patients' demographic data and tumor characteristics were similar in the groups. The off-clamp technique and sutureless technique rates in Group 2 were significantly higher than that in Group 1. Margin, ischemia, and complication score positivity was observed in 60% (n=15) of Group 1 and 96% (n=24) of Group 2. At receiver operating characteristic curve analysis, the 25th and later cases were statistically significant in terms of margin, ischemia, and complication score positivity. In terms of performing surgery with the off-clamp technique, the 28th and subsequent cases were statistically significant. CONCLUSION: A total of 25 or more cases appear to be sufficient to provide optimal surgical results in robotic retroperitoneal partial nephrectomy for an experienced surgeon.
RESUMO
INTRODUCTION: We aimed to present our experience of robot-assisted laparoscopic radical prostatectomy (RARP). MATERIAL AND METHODS: The study was a retrospective review of 500 patients who underwent RARP between March 2015 and July 2021 in our clinic. A transperitoneal approach was used in all patients. All patients had clinically organ-confined prostate cancer (≤ cT2c). RESULTS: The mean age of the patients was 64.6 ± 5.7 years. The median PSA was 11.4 ng/dL (range 0.3-92.7). The mean operative time was 183.5 min. Positive surgical margin rate was 19.4%. During a mean follow-up of 23.5 months, 96 patients (19.2%) received adjuvant radiotherapy due to the biochemical recurrence and 28 patients (16%) with lymph node positivity received early adjuvant hormone therapy. Considering the continence rates, 69% of the patients were total continence in the 3rd month, while this rate increased to 83 in the 6th month and 91% in the 12th month. CONCLUSION: RARP is a safe and feasible method for experienced centers with patient comfort, surgeon comfort, and successful oncological and functional results.
INTRODUCCIÓN: Nuestro objetivo fue presentar nuestra experiencia de prostatectomía radical laparoscópica asistida por robot (RARP). MATERIAL Y MÉTODOS: El estudio fue una revisión retrospectiva de 500 pacientes que se sometieron a una (RARP) entre marzo de 2015 y julio de 2021 en nuestra clínica. En todos los pacientes se utilizó un abordaje transperitoneal. Todos los pacientes tenían cáncer de próstata limitado al órgano clínicamente (≤ cT2c). RESULTADOS: La edad media de los pacientes fue de 64.6 ± 5.7 años. La mediana de PSA fue de 11.4 ng/dL (rango 0.3-92.7). El tiempo operatorio medio fue de 183.5 min. La tasa de márgenes quirúrgicos positivos fue del 19,4%. Durante un seguimiento medio de 23.5 meses, 96 pacientes (19.2%) recibieron radioterapia adyuvante debido a la recurrencia bioquímica y 28 pacientes (16%) con ganglios linfáticos positivos recibieron terapia hormonal adyuvante temprana. Considerando las tasas de continencia, el 69% de los pacientes tenían continencia total en el 3er mes, mientras que esa tasa aumentó a 83 en el 6° mes y 91% en el 12° mes. CONCLUSIÓN: RARP es un método seguro y factible para centros experimentados con comodidad para el paciente, comodidad para el cirujano y resultados oncológicos y funcionales exitosos.